Anticoagulant Agent - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anticoagulant Agent

The Experts below are selected from a list of 4437 Experts worldwide ranked by ideXlab platform

Anticoagulant Agent – Free Register to Access Experts & Abstracts

Ricardo Moreno-cabral – One of the best experts on this subject based on the ideXlab platform.

  • Delayed Management of Partial Aortic Valve Avulsion After Transcatheter Aortic Valve Replacement.
    The Annals of thoracic surgery, 2017
    Co-Authors: Dimitri Sherev, Khalid Azizi, Nassir A. Azimi, Susan Van Nordheim, Ricardo Moreno-cabral

    Abstract:

    We report a case of delayed treatment of a partial aortic valve leaflet avulsion during transcatheter aortic valve replacement (TAVR) and its successful management by a percutaneous snare retrieval technique. Post-TAVR transesophogeal echocardiography showed an avulsed native valve leaflet. We deferred retrieval of the mass with Anticoagulant Agents. One month later, a 30-mm EN-Snare was used to snare the mass. This case report demonstrates that the management of an avulsed aortic valve leaflet can be safely deferred with the use of an Anticoagulant Agent. Snare retrieval of the avulsed valve can be achieved under local anesthesia with close neurological monitoring.

Jurrien Ten M Berg – One of the best experts on this subject based on the ideXlab platform.

  • bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement the randomized bravo 3 trial
    Journal of the American College of Cardiology, 2015
    Co-Authors: George Dangas, Thierry Lefevre, Christian Kupatt, Didier Tchetche, Ulrich Schafer, Nicolas Dumonteil, John G Webb, Antonio Colombo, Stephan Windecker, Jurrien Ten M Berg

    Abstract:

    BACKGROUND

    Anticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be an effective alternative to heparin as the procedural Anticoagulant Agent in this setting.

    OBJECTIVES

    The goal of this study was to determine whether bivalirudin offers an alternative to heparin as the procedural Anticoagulant Agent in patients undergoing TAVR.

    METHODS

    A total of 802 patients with aortic stenosis were randomized to undergo transfemoral TAVR with bivalirudin versus unfractionated heparin during the procedure. The 2 primary endpoints were major bleeding within 48 h or before hospital discharge (whichever occurred first) and 30-day net adverse clinical events, defined as the combination of major adverse cardiovascular events (all-cause mortality, myocardial infarction, or stroke) and major bleeding.

    RESULTS

    Anticoagulation with bivalirudin versus heparin did not meet superiority because it did not result in significantly lower rates of major bleeding at 48 h (6.9% vs. 9.0%; relative risk: 0.77; 95% confidence interval [CI]: 0.48 to 1.23; p = 0.27) or net adverse cardiovascular events at 30 days (14.4% vs. 16.1%; relative risk: 0.89; 95% CI: 0.64 to 1.24; risk difference: -1.72; 95% CI: -6.70 to 3.25; p = 0.50); regarding the latter, the prespecified noninferiority hypothesis was met (pnoninferiority < 0.01). Rates of major adverse cardiovascular events at 48 h were not significantly different (3.5% vs. 4.8%; relative risk: 0.73; 95% CI: 0.37 to 1.43; p = 0.35). At 48 h, the bivalirudin group had significantly fewer myocardial infarctions but more acute kidney injury events than the heparin group; at 30 days, these differences were no longer significant. CONCLUSIONS In this randomized trial of TAVR procedural pharmacotherapy, bivalirudin did not reduce rates of major bleeding at 48 h or net adverse cardiovascular events within 30 days compared with heparin. Although superiority was not shown, the noninferiority hypothesis was met with respect to the latter factor. Given the lower cost, heparin should remain the standard of care, and bivalirudin can be an alternative Anticoagulant option in patients unable to receive heparin in TAVR. (International, Multi-center, Open-label, Randomized Controlled Trial in Patients Undergoing TAVR to Determine the Treatment Effect [Both Safety and Efficacy] of Using Bivalirudin Instead of UFH [BRAVO-2/3]; NCT01651780).

Dimitri Sherev – One of the best experts on this subject based on the ideXlab platform.

  • Delayed Management of Partial Aortic Valve Avulsion After Transcatheter Aortic Valve Replacement.
    The Annals of thoracic surgery, 2017
    Co-Authors: Dimitri Sherev, Khalid Azizi, Nassir A. Azimi, Susan Van Nordheim, Ricardo Moreno-cabral

    Abstract:

    We report a case of delayed treatment of a partial aortic valve leaflet avulsion during transcatheter aortic valve replacement (TAVR) and its successful management by a percutaneous snare retrieval technique. Post-TAVR transesophogeal echocardiography showed an avulsed native valve leaflet. We deferred retrieval of the mass with Anticoagulant Agents. One month later, a 30-mm EN-Snare was used to snare the mass. This case report demonstrates that the management of an avulsed aortic valve leaflet can be safely deferred with the use of an Anticoagulant Agent. Snare retrieval of the avulsed valve can be achieved under local anesthesia with close neurological monitoring.